Literature DB >> 18264564

Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.

Marie A Colucci1, Christopher J Moody, Gavin D Couch.   

Abstract

The quinone reductase enzyme NAD(P)H: quinone oxidoreductase 1 (NQO1) is a ubiquitous flavoenzyme that catalyzes the two-electron reduction of quinones. This Perspective briefly reviews the structure and mechanism, physiological role, and upregulation and induction of the enzyme, but focuses on the synthesis of new heterocyclic quinones and their metabolism by recombinant human NQO1. Thus a range of indolequinones, some of which are novel analogues of mitomycin C, benzimidazolequinones, benzothiazolequinones and quinolinequinones have been prepared and evaluated, leading to detailed knowledge of the structural requirements for efficient metabolism by the enzyme. Potent mechanism-based inhibitors (suicide substrates) of NQO1 have also been developed. These indolequinones irreversibly alkylate the protein, preventing its function both in standard enzyme assays and also in cells. Some of these quinones are also potent inhibitors of growth of human pancreatic cancer cells, suggesting a potential role for such compounds as therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18264564     DOI: 10.1039/b715270a

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  24 in total

1.  Antitumour indolequinones: synthesis and activity against human pancreatic cancer cells.

Authors:  Martyn Inman; Andrea Visconti; Chao Yan; David Siegel; David Ross; Christopher J Moody
Journal:  Org Biomol Chem       Date:  2014-07-21       Impact factor: 3.876

2.  Insight into the kinetics and thermodynamics of the hydride transfer reactions between quinones and lumiflavin: a density functional theory study.

Authors:  Clorice R Reinhardt; Tanner C Jaglinski; Ashly M Kastenschmidt; Eun H Song; Adam K Gross; Alyssa J Krause; Jonathan M Gollmar; Kristin J Meise; Zachary S Stenerson; Tyler J Weibel; Andrew Dison; Mackenzie R Finnegan; Daniel S Griesi; Michael D Heltne; Tom G Hughes; Connor D Hunt; Kayla A Jansen; Adam H Xiong; Sanchita Hati; Sudeep Bhattacharyya
Journal:  J Mol Model       Date:  2016-08-04       Impact factor: 1.810

3.  Characterization of the threshold for NAD(P)H:quinone oxidoreductase activity in intact sulforaphane-treated pulmonary arterial endothelial cells.

Authors:  Robert D Bongard; Gary S Krenz; Adam J Gastonguay; Carol L Williams; Brian J Lindemer; Marilyn P Merker
Journal:  Free Radic Biol Med       Date:  2011-01-14       Impact factor: 7.376

Review 4.  Targeting hypoxia in cancer therapy.

Authors:  William R Wilson; Michael P Hay
Journal:  Nat Rev Cancer       Date:  2011-06       Impact factor: 60.716

5.  Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: an alternative approach for chemotherapy of Leishmaniasis.

Authors:  Anil Kumar Shukla; Sanjukta Patra; Vikash Kumar Dubey
Journal:  Mol Cell Biochem       Date:  2011-02-26       Impact factor: 3.396

6.  Interplay of flavin's redox states and protein dynamics: an insight from QM/MM simulations of dihydronicotinamide riboside quinone oxidoreductase 2.

Authors:  Robyn M Mueller; Michael A North; Chee Yang; Sanchita Hati; Sudeep Bhattacharyya
Journal:  J Phys Chem B       Date:  2011-03-16       Impact factor: 2.991

7.  Sequestration of a highly reactive intermediate in an evolving pathway for degradation of pentachlorophenol.

Authors:  Itamar Yadid; Johannes Rudolph; Klara Hlouchova; Shelley D Copley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-15       Impact factor: 11.205

8.  Human NAD(P)H:quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups.

Authors:  Maria F Mendoza; Nicole M Hollabaugh; Suraj U Hettiarachchi; Robin L McCarley
Journal:  Biochemistry       Date:  2012-09-28       Impact factor: 3.162

9.  Receptor independent and receptor dependent CoMSA modeling with IVE-PLS: application to CBG benchmark steroids and reductase activators.

Authors:  Tomasz Magdziarz; Pawel Mazur; Jaroslaw Polanski
Journal:  J Mol Model       Date:  2008-10-21       Impact factor: 1.810

10.  Cyclic Changes in Active Site Polarization and Dynamics Drive the 'Ping-pong' Kinetics in NRH:Quinone Oxidoreductase 2: An Insight from QM/MM Simulations.

Authors:  Clorice R Reinhardt; Quin H Hu; Caitlin G Bresnahan; Sanchita Hati; Sudeep Bhattacharyya
Journal:  ACS Catal       Date:  2018-11-14       Impact factor: 13.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.